Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates that precisely target proteins critical to immune cell maturation and function, with the aim of addressing immune-mediated diseases, inflammatory diseases, and cancers. The company's business model is centered on leveraging its research and development capabilities to evaluate its proprietary product candidates in clinical trials across diverse disease areas with significant unmet needs. Corvus has not generated any revenue from product sales to date and has incurred significant operating losses since its inception in January 2014 ¹. The company expects these losses to continue and increase as it advances its product candidates through clinical development, seeks regulatory approvals, and prepares for potential commercialization ².

The company's core business model involves the discovery, development, and potential commercialization of novel therapeutic agents. Revenue generation is currently reliant on future regulatory approvals and subsequent product sales, or through collaboration agreements with third parties ³. The company's strategy emphasizes evaluating product candidates in clinical trials where the role of specific T cells in the target indication is understood, allowing for rapid progression from preclinical to clinical trials in various disease areas ⁴.

Corvus Pharmaceuticals has a product candidate pipeline featuring three clinical-stage assets: soquelitinib, ciforadenant, and mupadolimab. Soquelitinib (formerly CPI-818) is an investigational selective, orally bioavailable, covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), an enzyme involved in T cell activation, T cell receptor signaling, and T cell differentiation and function ⁵. The company believes soquelitinib has broad potential to inhibit inflammatory cytokines in diseases such as atopic dermatitis, hidradenitis suppurativa, asthma, psoriasis, and fibrotic diseases, and to enhance T cell function for tumor cell eradication ⁶. Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine, designed to block immunosuppressive adenosine in the tumor microenvironment and disable a tumor's ability to subvert immune attack ⁷. Mupadolimab is a humanized monoclonal antibody designed to react with a specific site on CD73, demonstrating binding to various immune cells and enhancement of immune responses by activating B cells ⁸.

Soquelitinib is currently in a registrational Phase 3 clinical trial for relapsed T cell lymphomas and a recently initiated randomized, placebo-controlled Phase 2 trial in patients with atopic dermatitis ⁹. Preclinical studies published in December 2024 demonstrated soquelitinib's selective binding and inhibition of ITK function, inhibition of Th2 T cell function and cytokine production leading to Th1 skewing, activation of cytotoxic killer cells, reduction of T cell exhaustion, and in vivo anti-tumor activity in several mouse tumor models ¹⁰. Final data from a Phase 1/1b clinical trial in relapsed T cell lymphomas, presented in December 2025, showed no dose-limiting toxicities or significant adverse events up to 600 mg twice-daily, with objective and durable tumor responses in the 200 mg twice-daily cohort, including 6 complete responses ¹¹. In patients with 1 to 3 prior therapies and adequate peripheral blood lymphocyte count (N=24), objective responses were seen in 9 patients, with a median progression-free survival of 6.2 months and a median overall survival of 28.1 months ¹². For atopic dermatitis, positive results from cohort 4 of a Phase 1 clinical trial, announced on January 20, 2026, showed a mean percent reduction in EASI for soquelitinib patients of 72% at day 56, compared to 40% for placebo patients ¹³.

Ciforadenant is being evaluated in an open-label Phase 1b/2 clinical trial as a first-line therapy for metastatic RCC in combination with ipilimumab and nivolumab, in collaboration with the Kidney Cancer Research Consortium ¹⁴. An interim analysis performed on May 31, 2024, met the interim threshold for efficacy, and enrollment has been completed ¹⁵. Mupadolimab is in clinical development for various solid tumors, but the company is prioritizing the development of its other two lead product candidates before initiating a potential Phase 2 randomized clinical trial ¹⁶.

For the fiscal year ended December 31, 2025, Corvus Pharmaceuticals reported a net loss of $15.3 million ¹⁷, an improvement from a net loss of $62.3 million in 2024 ¹⁸ and $27.0 million in 2023 ¹⁹. Total operating expenses for 2025 were $42.971 million ²⁰, comprising $33.719 million in research and development expenses ²¹ and $9.252 million in general and administrative expenses ²². This compares to total operating expenses of $27.548 million in 2024 ²³ and $23.407 million in 2023 ²⁴. The company also reported interest income and other expense, net, of $2.505 million in 2025 ²⁵, a change in fair value of warrant liability of $27.141 million ²⁶, and a loss from equity method investment of $1.958 million ²⁷. As of December 31, 2025, the company had cash, cash equivalents, and marketable securities of $56.8 million ²⁸ and an accumulated deficit of $412.3 million ²⁹.

Year-over-year comparisons show a significant increase in research and development expenses, rising by $14.334 million from $19.385 million in 2024 to $33.719 million in 2025 ³⁰. This increase was primarily driven by a $4.8 million increase in drug manufacturing costs, a $6.0 million increase in clinical trial expenses, and a $1.6 million increase in other outside service costs for soquelitinib ³¹. General and administrative expenses also increased by $1.089 million, from $8.163 million in 2024 to $9.252 million in 2025 ³², mainly due to a $1.3 million increase in personnel and related costs ³³. The net loss decreased substantially from $62.3 million in 2024 to $15.3 million in 2025, primarily due to a $60.518 million positive change in the fair value of warrant liability ³⁴.

Significant operational developments during the period include the initiation of a registrational Phase 3 clinical trial for soquelitinib in relapsed PTCL in the third quarter of 2024 ³⁵. The Phase 1 clinical trial for soquelitinib in atopic dermatitis completed enrollment in cohort 4 as of January 15, 2026, with positive results leading to plans for a Phase 2 trial in the first quarter of 2026 ³⁶. The company also completed enrollment in the Phase 1b/2 clinical trial for ciforadenant in metastatic RCC ³⁷. In May 2024, Corvus completed a registered direct offering, selling common stock, pre-funded warrants, and common stock warrants for net proceeds of approximately $30.3 million, and received $54.3 million from the exercise of common stock warrants ³⁸.

Corvus Pharmaceuticals expects its existing capital resources, including the net proceeds from its January 2026 financing, to be sufficient to fund its planned operations into the second quarter of 2028 ³⁹. However, the company explicitly states that it will need to raise additional capital in the future to fund all of its ongoing and planned development programs through commercialization ⁴⁰. Management believes its current cash, cash equivalents, and marketable securities of $56.8 million as of December 31, 2025, combined with the approximate net proceeds of $189.4 million from the January 2026 follow-on public offering, will support operations for at least the next 12 months from the issuance date of the consolidated financial statements ⁴¹.

A major growth area for the company is the continued development of soquelitinib. Following positive Phase 1 results in atopic dermatitis, Corvus plans to initiate a Phase 2 clinical trial for soquelitinib in patients with moderate-to-severe atopic dermatitis who have failed at least one prior topical or systemic therapy in the first quarter of 2026 ⁴². This trial is anticipated to enroll approximately 200 patients across four cohorts, testing soquelitinib doses of 200 mg once per day, 200 mg twice per day, and 400 mg once per day, alongside a placebo group, with a planned 12-week treatment period and a 30-day follow-up ⁴³. The company also plans a potential clinical trial for soquelitinib in asthma and another in hidradenitis suppurativa ⁴⁴. The proposed mechanism of action for soquelitinib, involving ITK inhibition and immune rebalancing, is believed to support its potential in a wide range of inflammatory and immune diseases ⁴⁵.

Another growth area involves the next-generation ITK inhibitor preclinical product candidates, which are designed to deliver precise T-cell modulation optimized for specific immunology indications ⁴⁶. These candidates are part of ongoing business development efforts to maximize the potential of the ITK inhibitor programs and other programs ⁴⁷.

Operationally, the company anticipates increasing its research and development expenses substantially as it continues the development and potential commercialization of its product candidates ⁴⁸. This includes costs associated with the enrollment and completion of the ongoing Phase 3 registrational clinical trial for soquelitinib in PTCL, completion of the ongoing Phase 1 clinical trial for soquelitinib in atopic dermatitis, completion of the Phase 1b/2 clinical trial with ciforadenant, and process development and manufacturing of drug supply for soquelitinib ⁴⁹. The company also expects to increase its headcount to support continued research and development and potential commercialization efforts, which will lead to increased general and administrative expenses ⁵⁰.

Regarding capital allocation, Corvus plans to finance its future cash needs through a combination of public or private equity or debt financings or other sources, such as strategic collaborations ⁵¹. The company has reserved 25,711,425 shares of common stock for issuance as of December 31, 2025, including 8,275,913 pre-funded warrants, 3,007,335 shares available for future option grants, 14,028,177 outstanding options, and 400,000 shares reserved for an employee stock purchase plan ⁵².

The company explicitly flags that its operating plan may change due to many factors, including the type, number, scope, progress, and results of its ongoing and planned clinical trials, the costs of obtaining and maintaining intellectual property rights, and the costs and timing of manufacturing and establishing sales and marketing capabilities ⁵³. Macroeconomic conditions such as rising inflation are also identified as a factor that could impact results of operations ⁵⁴. Furthermore, the company highlights that its ability to raise additional capital through sales of common stock may face difficulties due to factors such as impacts of pandemics and increases in inflation rates or interest rates or the broad imposition of tariffs and other trade controls ⁵⁵.

Corvus Pharmaceuticals faces several material risks, including significant operating losses since inception and the expectation of continued losses for the foreseeable future, with an accumulated deficit of $412.3 million as of December 31, 2025 ⁵⁶. The company will require substantial additional financing to achieve its goals, and a failure to obtain necessary capital could force delays or termination of product development and commercialization efforts ⁵⁷. Clinical drug development is a lengthy, expensive process with uncertain outcomes, and preclinical and early clinical trial results are not necessarily predictive of future success, potentially leading to product candidates failing or suffering delays ⁵⁸. The company relies on third parties for clinical trials and manufacturing, and their unsatisfactory performance or failure to meet deadlines could delay or derail development programs ⁵⁹. Regulatory compliance is costly and time-consuming, with potential for unanticipated delays or denial of approvals, and the FDA may not accept data from foreign trials ⁶⁰. The occurrence of serious complications or side effects from product candidates could lead to discontinuation of development, refusal of regulatory approval, or post-approval revocation of marketing authorizations ⁶¹. Commercialization efforts face risks including market acceptance, competition from companies with greater resources, and potential government price controls, particularly in the EU where pricing negotiations can be lengthy ⁶². Changes in U.S. and foreign healthcare laws, such as the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act of July 2025, could limit coverage and reimbursement, and impose price negotiations or significant reductions in Medicaid funding ⁶³. The company's information technology systems are vulnerable to cyberattacks and security breaches, which could disrupt development programs, lead to data loss, or result in legal claims and penalties ⁶⁴.

Management's message to shareholders emphasizes the company's focus as a clinical-stage biopharmaceutical entity dedicated to developing product candidates that precisely target proteins critical to immune cell maturation and function, with broad potential in immune-mediated diseases, inflammatory diseases, and cancers. They highlight the strategy of leveraging research and development capabilities to evaluate product candidates in clinical trials where the role of specific T cells is understood, enabling rapid progression in diverse disease areas with large unmet needs. Management explicitly states that the company has incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future, anticipating these losses will increase as development, regulatory approval, and potential commercialization efforts for soquelitinib and other product candidates continue. They project that existing capital resources, including the approximate net proceeds of $189.4 million ⁶⁵ from the January 2026 follow-on public offering, will be sufficient to fund operations into the second quarter of 2028 ⁶⁶. The three strategic priorities emphasized for the period ahead are the continued advancement of soquelitinib, including its registrational Phase 3 clinical trial for relapsed T cell lymphomas and the planned Phase 2 trial in atopic dermatitis in the first quarter of 2026, the completion of the Phase 1b/2 clinical trial for ciforadenant, and the ongoing business development efforts for next-generation ITK inhibitor preclinical product candidates.